Matinas Biopharma Holdings, Inc.
MTNB Healthcare Biotechnology
In the quarter to June 2026, EPS grew 79.9%, free cash flow grew 9.15% and total debt fell 54.5%, each against the same quarter a year earlier.
Follow MTNB
Matinas Biopharma Holdings, Inc. (MTNB) EV/Sales
As of 16 October 2026, Matinas Biopharma Holdings, Inc. (MTNB) trades at a EV/Sales of 0.0×. Over the past ten years it has ranged from −254× (April 2020) to 54.9× (March 2017); the current reading is higher than 91% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | −2.5× | — |
| FY2022 | −6.6× | — |
| FY2021 | −186× | — |
| FY2020 | −121× | — |
| FY2019 | −23.5× | — |
| FY2018 | −40.8× | — |
| FY2017 | 0.6× | — |
| FY2015 | −2.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2023 | −4.2× | — |
| Dec 2022 | −6.6× | — |
| Sep 2022 | −9.4× | — |
| Jun 2022 | −20.1× | — |
| 15 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ELAB PMGC Holdings Inc. compare | −6.7× |
| KAPA Kairos Pharma, Ltd. compare | n/m |
| BPTSY Biophytis SA Sponsored ADR compare | n/m |
| MTNB Matinas Biopharma Holdings, Inc. | 0.0× |
| EIGRQ Eiger BioPharmaceuticals, Inc. compare | 4.4× |
| VBIO Valion Bio, Inc. compare | 11.3× |
| NTBLQ Notable Labs, Ltd. compare | 23.3× |
| WINT Windtree Therapeutics, Inc. compare | 63.8× |
| BIORQ Biora Therapeutics, Inc. compare | 67.4× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)